tyb
DEEPC04 P-3 Orion finished with it's runs north of Port Angeles and returning to NAS Whidbey Island
VVLL843 VVLL844 P-8 Poseidens out of NAS Jax. 843 over Wilmington low altitude (been here several times over last few weeks) and 844 is done with Columbia and eastn.
PAT053 C-560 sw from JBA
Alphabet CEO Sundar Pichai made $280.6 million in 2019: proxy statement
Sundar Pichai, chief executive of Google parent Alphabet Inc. made $280.6 million in compensation in 2019, including $276.6 million in stock compensation, according to a proxy statement filed by the company Friday. Alphabet Chief Financial Officer Ruth Porat and Chief Legal Officer David Drummond, who left the company on Jan. 31 following a sexual-misconduct investigation, each made more than $47 million last year. Google co-founders Larry Page and Sergey Brin, who last year stepped away from day-to-day operation of the company, each made $1 in 2019. Alphabet also announced its annual share meeting will be held virtually on June 3.
https://www.marketwatch.com/story/alphabet-ceo-sundar-pichai-made-2806-million-in-2019-proxy-statement-2020-04-24
SAM630 G5 east from Peterson AFB and over 500kts-from JBA earlier
same here. The "crazy" nigga's will be known as the smart nigga's.
Aimmune Therapeutics bought by Nestle S.A.: $200m-February 24th
Logo Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase. Number of employees : 275 people.
https://www.marketscreener.com/AIMMUNE-THERAPEUTICS-INC-23306014/company/
Société des Produits Nestlé S.A. in Vevey is a Company limited by shares (AG) from the sector «Production of comestibles». Société des Produits Nestlé S.A. is active.
The management of the company Société des Produits Nestlé S.A. consists of 35 persons. The foundation of the company took place on 19.09.1929.
The last commercial register change was made on 03.10.2019.
The company Société des Produits Nestlé S.A. has currently registered 2677 different trademarks or applications for trademarks.
On the same address as Société des Produits Nestlé S.A. there are 9 other active companies registered. These include: DPA (Holding) SA, Fonds de Pensions Complémentaire Nestlé (Fondation Louis Dapples), FONDS DE PENSIONS NESTLE (Fondation Edouard Muller).
https://www.moneyhouse.ch/en/company/societe-des-produits-nestle-s-a-10645859331
https://www.finviz.com/insidertrading.ashx?oc=1803539&tc=7